-
Product Insights
NewSecondary Progressive Multiple Sclerosis (SPMS) – Drugs In Development, 2024
Empower your strategies with our Secondary Progressive Multiple Sclerosis (SPMS) – Drugs In Development, 2024 report and make more profitable business decisions. Secondary progressive multiple sclerosis (SPMS) is a form of MS that follows relapsing-remitting MS (RRMS). In RRMS, people experience periods of relapses, when symptoms get worse, and remissions, when symptoms get better. In SPMS, symptoms gradually worsen over time without any clear relapses or remissions. SPMS usually occurs 10 to 15 years after the first MS symptoms, but it...
-
Product Insights
NewLeiomyosarcoma – Drugs In Development, 2024
Empower your strategies with our Leiomyosarcoma – Drugs In Development, 2024 report and make more profitable business decisions. Leiomyosarcoma is an aggressive soft tissue sarcoma derived from smooth muscle cells typically of uterine, gastrointestinal, or soft tissue origin. Symptoms include a noticeable lump or swelling; pain, if it presses on nerves or muscles; and a blockage in the stomach or intestines or gastrointestinal bleeding if the tumor is located in the abdomen or digestive tract. Predisposing factors include age, chemical exposure,...
-
Product Insights
NewRelapsing Remitting Multiple Sclerosis (RRMS) – Drugs In Development, 2024
Empower your strategies with our Relapsing Remitting Multiple Sclerosis (RRMS) – Drugs In Development, 2024 report and make more profitable business decisions. Relapsing-remitting multiple sclerosis (RRMS) is the most common form of multiple sclerosis (MS), a chronic autoimmune condition that affects the central nervous system. In RRMS, individuals experience intermittent episodes of new or worsening symptoms (relapses or exacerbations) lasting days to weeks, followed by periods of partial or complete recovery (remission) with stable or improved function. Symptoms of RRMS can...
-
Product Insights
NewLiposarcoma – Drugs In Development, 2024
Empower your strategies with our Liposarcoma – Drugs In Development, 2024 report and make more profitable business decisions. Liposarcoma is a rare tumor derived from fat tissue that occurs in the “soft tissues” of the body (soft tissue sarcoma). It is classified as a cancer (malignant) because of its potential to recur locally and spread to other areas of the body. The severity of disease depends on the subtype of the liposarcoma and the presenting stage of the primary tumor....
-
Product Insights
NewNon-Rhabdomyosarcoma – Drugs In Development, 2024
Empower your strategies with our Non-Rhabdomyosarcoma – Drugs In Development, 2024 report and make more profitable business decisions. Non-rhabdomyosarcoma refers to a group of cancers that are distinct from rhabdomyosarcoma, a type of soft tissue cancer that arises from skeletal muscle cells. Non-rhabdomyosarcoma includes various types of soft tissue sarcomas that originate in tissues such as nerves, blood vessels, fat, and connective tissues. These sarcomas can occur in different parts of the body, and their characteristics and treatment approaches vary. Common...
-
Product Insights
NewHuman Papillomavirus (HPV) Associated Cancer – Drugs In Development, 2024
Empower your strategies with our Human Papillomavirus (HPV) Associated Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Human papillomavirus (HPV) is the most common viral infection of the reproductive tract. Human papillomavirus (HPV) has been found to be associated with several types of cancer. Risk factors include smoking, weakened immune system, long-term oral contraceptive use, and chronic inflammation. Human papillomavirus (HPV)-associated cancer has no symptoms until it is quite advanced, very serious, and hard to treat....
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rusfertide Acetate in Hemochromatosis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Rusfertide Acetate in Hemochromatosis Drug Details: PTG-300 is under development for the treatment of iron...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – H3 Mrna/Lnp Vaccine in Influenza A Virus, H3N2 Subtype Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - H3 Mrna/Lnp Vaccine in Influenza A Virus, H3N2 Subtype Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.H3 Mrna/Lnp Vaccine in Influenza A Virus,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Favezelimab in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Favezelimab in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Favezelimab in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Drug Details:Favezelimab (MK-4280) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ATX-101 in Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ATX-101 in Ovarian Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.ATX-101 in Ovarian Cancer Drug Details:ATX-101 is under development for the treatment of...